Literature DB >> 34697664

Immunosuppression and Kidney Transplantation.

Jeanne Kamal1, Alden Doyle2.   

Abstract

Immunosuppression is complex, fraught with on-target and off-target adverse effects, and hard to get right but is the key to successful allotransplantation. Herein, we review the key immunosuppressive agent classes used for kidney transplant, highlighting mechanisms of action and typical clinical use.
© 2021. Springer Nature Switzerland AG.

Entities:  

Keywords:  Antibody mediation rejection; Calcineurin inhibitors; Immunosuppression; Induction therapy; Kidney transplantation; Rejection; T-cell depleting agents; Transplant protocols

Mesh：

Substances：

Year:  2022        PMID： 34697664     DOI： 10.1007/164_2021_546

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN： 0171-2004


  43 in total

1.  A study of the effects of drugs in prolonging survival of homologous renal transplants in dogs.

Authors:  R Y CALNE; G P ALEXANDRE; J E MURRAY
Journal:  Ann N Y Acad Sci       Date:  1962-10-24       Impact factor: 5.691

Review 2.  The purine path to chemotherapy.

Authors:  G B Elion
Journal:  Science       Date:  1989-04-07       Impact factor: 47.728

3.  Mycophenolate mofetil: a decade of clinical experience.

Authors:  Gabriel M Danovitch
Journal:  Transplantation       Date:  2005-10-15       Impact factor: 4.939

4.  Reduced exposure to calcineurin inhibitors in renal transplantation.

Authors:  Henrik Ekberg; Helio Tedesco-Silva; Alper Demirbas; Stefan Vítko; Björn Nashan; Alp Gürkan; Raimund Margreiter; Christian Hugo; Josep M Grinyó; Ulrich Frei; Yves Vanrenterghem; Pierre Daloze; Philip F Halloran
Journal:  N Engl J Med       Date:  2007-12-20       Impact factor: 91.245

Review 5.  PharmGKB summary: cyclosporine and tacrolimus pathways.

Authors:  Julia M Barbarino; Christine E Staatz; Raman Venkataramanan; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2013-10       Impact factor: 2.089

6.  Hazard of combining allopurinol and thiopurine.

Authors:  A Berns; S Rubenfeld; W T Rymzo; J J Calabro
Journal:  N Engl J Med       Date:  1972-03-30       Impact factor: 91.245

7.  Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial.

Authors:  K Budde; S Bunnapradist; J M Grinyo; K Ciechanowski; J E Denny; H T Silva; L Rostaing
Journal:  Am J Transplant       Date:  2014-10-02       Impact factor: 8.086

8.  Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function.

Authors:  A B Adams; J Goldstein; C Garrett; R Zhang; R E Patzer; K A Newell; N A Turgeon; A S Chami; A Guasch; A D Kirk; S O Pastan; T C Pearson; C P Larsen
Journal:  Am J Transplant       Date:  2017-07-03       Impact factor: 8.086

9.  Rabbit antithymocyte globulin versus basiliximab in renal transplantation.

Authors:  Daniel C Brennan; John A Daller; Kathleen D Lake; Diane Cibrik; Domingo Del Castillo
Journal:  N Engl J Med       Date:  2006-11-09       Impact factor: 91.245

Review 10.  Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.

Authors:  L Alinari; R Lapalombella; L Andritsos; R A Baiocchi; T S Lin; J C Byrd
Journal:  Oncogene       Date:  2007-05-28       Impact factor: 9.867
View more
  1 in total

1.  Editorial: Insights in renal pharmacology: 2021.

Authors:  Norberto Perico; Matthew D Griffin; Giuseppe Remuzzi
Journal:  Front Pharmacol       Date:  2022-09-07       Impact factor: 5.988
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.